Otava propose new Kinase focused libraries.
The libraries have been designed with QSAR using training set of compounds active towards various Protein Kinase targets .
The libraries contain only drug-like compounds having the following predicted activities:
1-Phosphatidylinositol-
Abl kinase inhibitor
Acetate kinase inhibitor
ADP-thymidine kinase inhibitor
Aurora kinase inhibitor
Aurora-B kinase inhibitor
Aurora-C kinase inhibitor
Beta-adrenergic receptor kinase inhibitor
Check point kinase inhibitor
Cyclin-dependent kinase 1 inhibitor
Cyclin-dependent kinase 2 inhibitor
Cyclin-dependent kinase 4 inhibitor
Cyclin-dependent kinase inhibitor
EphB2 kinase inhibitor
Epidermal growth factor receptor kinase inhibitor
Glycogen synthase kinase-3 inhibitor
G-protein-coupled receptor kinase inhibitor
Guanidinoacetate kinase inhibitor
I kappa B kinase 2 inhibitor
Inositol-trisphosphate 3-kinase inhibitor
Lombricine kinase inhibitor
MAP kinase inhibitor
N-acylmannosamine kinase inhibitor
NADH kinase inhibitor
Opheline kinase inhibitor
Phosphatidylinositol 3-kinase beta inhibitor
Phosphatidylinositol 3-kinase gamma inhibitor
Phosphoenolpyruvate carboxykinase (diphosphate)
Platelet derived growth factor receptor kinase inhibitor
Protein kinase (CK1) inhibitor
Protein kinase B inhibitor
Protein kinase C eta inhibitor
Protein-serine-
Proto-oncogene tyrosine-protein kinase Fyn inhibitor
Proto-oncogene tyrosine-protein kinase Kit inhibitor
Pyridoxal kinase inhibitor
Raf kinase B inhibitor
Raf kinase inhibitor
Rho-associated kinase inhibitor
Ribosomal protein S6 kinase inhibitor
Shikimate kinase inhibitor
Smooth muscle myosin light chain kinase inhibitor
Sphinganine kinase inhibitor
Sphingosine kinase inhibitor
Src kinase inhibitor
Taurocyamine kinase inhibitor
Thymidine kinase inhibitor
Tyrosine kinase inhibitor
Urokinase inhibitor
All compounds are in stock, cherry-picking is available. These libraries are proposed for screening in Kinase-associated research and drug development.
